|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma显示文摘 | Krasner C Joyce RM | 2001 | Curr Pharm Biotechnol2001，2，4： | 1 |
| 2 | Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma 显示文摘 | Krasner C Joyce RM | 2001 | Curr Pharm Biotechnol2001，2，4： | 1 |
| 3 | Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity 显示文摘 | Murphy EF Cotter PD Hogan A O'Sullivan O Joyce A Fouhy F Clarke SF Marques TM O'Toole PW Stanton C Quigley EM Daly C Ross PR OtDoherty RM Shanahan F | 2013 | Gut2013，62，2： | 1 |
| 4 | Zevalin:90yttrium labeled anti - Cd20(ibritumormab tiuxetan), a new treatment for non - Hodgkin' s lymphoma 显示文摘 | Krasner C Joyce RM | 2001 | Curr Pharm Biotechnol2001，2，4： | 1 |
| 5 | Role of transforming growth factor-beta infracture healing显示文摘 | 13,Joyce ME Terek RM Jingushi S | 1990 | Ann N Y Acad Sci1990，593，1： | 1 |
| 6 | Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus 显示文摘 | Liao HX Lynch R Zhou T Gao F Alam SM Boyd SD Fire AZ Roskin KM Schramm CA Zhang Z ZhuJ Sha- piro L NISC Comparative Sequencing Program Mullikin JC Gnanakaran S Hraber P Wiehe K Kelsoe G Yang G Xia SM Montefiori DC Parks R Lloyd KE Scearce RM Soderberg KA Cohen M Kamanga G Louder MK Tran LM Chen Y Cai F Chen S Moquin S Du X Joyce MG Srivatsan S Zhang B Zheng A Shaw GM Hahn BH Kepler TB Korber BT Kwong PD Mascola JR Haynes BF | 2013 | Nature2013，496，7446： | 1 |
| 7 | Rituximab and ifosfamide, mitoxantrone, etoposide(RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autolngous haematopoietic transplate显示文摘 | Joyce RM Kraser CN Tetrealt JC | 2001 | Eur J Haematol2001，66，64： | 1 |
| 8 | A phase Ⅰ-Ⅱ study of rituximab,ifosfamide,mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT)显示文摘 | JOYCE RM REGAN M OTTAWAY J | 2003 | Ann Oncol2003，14，1： | 1 |
| 9 | A phase I2II study of rituximab, ifosfamide, mitoxantrone and etoposide (R2IME)forBeellnon2Hodgkins' lyrnphoma prior to and after- high2dose chemo2therapy and autologous stem cell transplanta- tion (HDC2ASCT)显示文摘 | JOYCE RM REGANM OTrAWAY J etal | 2003 | Ann Oncol2003，14，1： | 1 |
| 10 | Role of transforming growth factor-β in fracture repair显示文摘 | JoyCe ME Terek RM Jingyshis | | 0，，01： | 1 |
| 11 | Zevalin: 90-Yttrium labeled antiCD20 (Ibritumomabtiuxetan), a new treatment for non-Hodgkin's lymphoma显示文摘 | Krasner C Joyce RM | 2001 | Curr Pharm Biotechol2001，2，4： | 1 |
| 12 | A phase Ⅰ-Ⅱ study of rituximab, ifosfamide, mitoxantrone and etoposide (R-ME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stern cell transplantation (HDC-ASCT)显示文摘 | JOYCE RM REGAN M OTTAWAY J | 2003 | Ann Oncol2003，14，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员